Pacer Advisors, Inc. Editas Medicine, Inc. Transaction History

Pacer Advisors, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$4.67 - $7.28 $11,796 - $18,389	-2,526 Reduced 67.4%	1,222 $5,000
Q1 2024 May 10, 2024	BUY	$7.03 - $11.07 $26,348 - $41,490	3,748 New	3,748 $27,000
Q2 2021 Jul 21, 2021	SELL	$31.29 - $56.64 $52,629 - $95,268	-1,682 Closed	0 $0
Q1 2021 Apr 05, 2021	SELL	$39.71 - $90.58 $17,869 - $40,761	-450 Reduced 21.11%	1,682 $71,000
Q4 2020 Jan 20, 2021	SELL	$27.07 - $84.35 $42,012 - $130,911	-1,552 Reduced 42.13%	2,132 $149,000
Q3 2020 Oct 19, 2020	BUY	$28.06 - $37.16 $103,373 - $136,897	3,684 New	3,684 $103,000
Q4 2018 Feb 13, 2019	SELL	$18.19 - $31.79 $135,224 - $236,326	-7,434 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$27.65 - $38.39 $205,550 - $285,391	7,434 New	7,434 $237,000
Q1 2018 May 14, 2018	SELL	$29.84 - $44.08 $54,458 - $80,446	-1,825 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$21.89 - $31.34 $39,949 - $57,195	1,825	1,825 $56,000

244

56.8M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Pacer Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Pacer Advisors, Inc. with notifications on news.